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Abstract
Epstein-Barr virus (EBV) induces an uncoordinated S-phase-like cellular environment coupled with multiple prophase-like
events in cells replicating the virus. The EBV encoded Ser/Thr kinase BGLF4 has been shown to induce premature
chromosome condensation through activation of condensin and topoisomerase II and reorganization of the nuclear lamina
to facilitate the nuclear egress of nucleocapsids in a pathway mimicking Cdk1. However, the observation that RB is
hyperphosphorylated in the presence of BGLF4 raised the possibility that BGLF4 may have a Cdk2-like activity to promote S-
phase progression. Here, we investigated the regulatory effects of BGLF4 on cell cycle progression and found that S-phase
progression and DNA synthesis were interrupted by BGLF4 in mammalian cells. Expression of BGLF4 did not compensate
Cdk1 defects for DNA replication in S. cerevisiae. Using time-lapse microscopy, we found the fate of individual HeLa cells was
determined by the expression level of BGLF4. In addition to slight cell growth retardation, BGLF4 elicits abnormal
chromosomal structure and micronucleus formation in 293 and NCP-TW01 cells. In Saos-2 cells, BGLF4 induced the
hyperphosphorylation of co-transfected RB, while E2F1 was not released from RB-E2F1 complexes. The E2F1 regulated
activities of the cyclin D1 and ZBRK1 promoters were suppressed by BGLF4 in a dose dependent manner. Detection with
phosphoamino acid specific antibodies revealed that, in addition to Ser780, phosphorylation of the DNA damage-
responsive Ser612 on RB was enhanced by BGLF4. Taken together, our study indicates that BGLF4 may directly or indirectly
induce a DNA damage signal that eventually interferes with host DNA synthesis and delays S-phase progression.
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Introduction
Epstein-Barr virus (EBV) is a human herpesvirus which infects
most of the human population worldwide. EBV is the causal agent
of infectious mononucleosis and is highly associated with human
malignant diseases, such as Burkitt’s lymphoma, Hodgkin’s
disease, nasopharyngeal carcinoma (NPC), T cell lymphoma and
gastric carcinoma [1]. EBV becomes latent in long-lived B cells
after primary infection. Following various stimuli, the latent virus
can be reactivated through the expression of two immediate early
transactivators, Zta and Rta, which turn on a cascade of lytic gene
expression and EBV replication [2].
EBV has evolved various strategies to optimize the host cell
environment for viral replication and virion production and
achieve a sophisticated balance between the use of host and viral
machineries during lytic replication. The expression of S-phase
cyclins, cyclin E and cyclin A, is up-regulated and leads to an
increase in the associated S-phase Cdk activity and RB hyperpho-
sphorylation in cells replicating EBV. Inhibition of S-phase Cdk by
chemical Cdk inhibitors blocks the expression of immediate early
and early genes and prevents lytic cycle progression, suggesting
that S-phase Cdk activity is required for efficient initiation of lytic
EBV replication [3]. However, it is worth noting that cellular
DNA replication is blocked at the G1/S boundary upon EBV lytic
cycle induction [4]. It has been speculated that the S-phase-like
environment may provide materials for viral DNA replication and
competition from host DNA replication is blocked by viral factors.
In addition, a DNA damage response (DDR) is elicited during lytic
EBV replication by activation of the ATM checkpoint signaling
pathway, which has been proved to be required for the progression
of virus replication [5]. On the other hand, repetitive reactivation
of EBV was shown to promote genomic instability and tumor
progression in NPC cells, suggesting viral factors may affect cell
growth control or cell cycle progression [6].
EBV BGLF4 is a proline-dependent Ser/Thr protein kinase,
which belongs to the family of conserved herpesvirus protein
kinases (CHPKs). CHPKs are encoded by all herpesviruses and
include UL13 of HSV-1, UL97 of HCMV, BGLF4 of EBV, U69
of human herpesvirus 6 (HHV6) and ORF36 of Kaposi sarcoma-
associated herpesvirus (KSHV) [7,8]. CHPKs are highly con-
served with Cdks in the catalytic domain and were first shown to
phosphorylate target sites of Cdk1 of cellular elongation factor
1delta (EF-1d) [9]. As a result, there is the possibility that CHPKs
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[7,8]. A number of substrates of Cdk1 were later shown to be
phosphorylated by BGLF4, including p27
KIP1, MCM4, conden-
sin, Topo II, lamin A/C. BGLF4 phosphorylates and induces the
degradation of Cdk inhibitor p27
KIP upon lytic EBV replication,
contributing to the establishment of an S-phase cellular environ-
ment, which is favorable for viral replication [10]. BGLF4 was
shown to inactivate the MCM4-6-7 complex-associated DNA
helicase through MCM4 phosphorylation and slow down the
growth of HeLa cells, indicating that BGLF4 may have an
inhibitory effect on host DNA replication [11]. Previously, we
found that BGLF4 alone can induce cellular chromosome
condensation through phosphorylation of condensin and activa-
tion of Topoisomerase II (Topo II) [12]. Moreover, BGLF4
participates in the regulation of efficient nuclear egress through
phosphorylation of lamin A/C and disassembly of the nuclear
lamina, mimicking Cdk1 activity at prophase [13]. However,
BGLF4 actually has a broader substrate specificity than Cdk1. In
an EBV-protein array phosphorylation assay, 10 of the 21 BGLF4
substrates were found to be substrates for Cdk1/cyclin B, while 10
of 12 Cdk1/cyclin B substrates were BGLF4 substrates [14]. Our
previous study also pointed out that BGLF4 targets more residues
on lamin A/C than does Cdk1 [13]. Conceivably, because BGLF4
activity is not inhibited by Cdk inhibitor, BGLF4 may be involved
in more cellular regulation than Cdk1 [10,13]. On the other hand,
the Cdk-like function of CHPKs was examined recently by
another group. It was found that beta- and gamma-, but not
alpha-, CHPKs, share Cdk-like activity and phosphorylate RB at
the Cdk4 and Cdk2 targeting residues, Ser780, 807 and Thr821,
and promote bud growth in temperature-sensitive mutant yeasts in
a compensation assay [15]. It was proposed by the authors that
BGLF4 may also possesses Cdk-2 like activity to promote S-phase
progression through RB phosphorylation [15].
In addition to Cdk-like activity, BGLF4 alone is capable of
inducing H2AX phosphorylation in the absence of other viral
proteins or agents inducing DNA damage [16]. More recently,
BGLF4 was shown to phosphorylate and activate TIP60, a histone
acetyltransferase regulating chromatin remodeling and responsive
to DDR [17]. The BGLF4-mediated activation of TIP60 is
required for autophosphorylation of ATM and expression of lytic
genes, suggesting BGLF4 plays an essential role in the upstream
process of DNA damage signaling, to facilitate viral replication.
Here we aimed to clarify the contradictory observations
regarding BGLF4-induced phenomena and to determine the
effects of BGLF4 on cell growth and cell cycle control in
mammalian and yeast systems. The outcome of the BGLF4 kinase
activity on cellular chromosome stability also was monitored. We
show that BGLF4-elicited RB hyperphosphorylation does not lead
to cell cycle progression or the activation of E2F1 responsive
promoters. In addition to Ser780, BGLF4 induces the phosphor-
ylation of RB at Ser612, which is an indication of DDR. In
addition, BGLF4 elicits the formation of micronuclei in NPC-
TW01 derived cell lines, suggesting that BGLF4 induces a DNA
damage signal and causes the phosphorylation of RB at Ser612
that eventually interferes with host DNA synthesis and delays S-
phase progression.
Results
BGLF4 Interferes with Cellular DNA Synthesis and S-
phase Progression
In our previous studies, we found that BGLF4 induces
prophase-like events, including unscheduled chromosome con-
densation and disassembly of nuclear lamina, independent of the
cell cycle stage [12,13]. In addition, BGLF4 was found to repress
the activity of DNA helicase MCM4-6-7, implying that expression
of BGLF4 does not favor cellular DNA synthesis [11]. In contrast,
a recent study reported that EBV BGLF4 and its homologues in
beta and gamma-herpesviruses elicit RB hyperphosphorylation
and promote bud growth of a temperature-sensitive mutant yeast
cdc28-13, suggesting BGLF4 has the potential to advance S-phase
progression [15]. Here, we aimed to clarify the paradoxical effects
of BGLF4 on cell growth and cell cycle progression.
The DNA content of cells with BGLF4 expression was first
analyzed in HeLa cells transiently transfected with GFP, GFP-
BGLF4 or GFP-K102I (kinase dead mutant) plasmid. To ensure
the levels of ectopically expressed BGLF4 in HeLa cells were
comparable to cells replicating the virus, we compared the
expression levels in BGLF4-expressing HeLa cells to those in
various reactivated EBV positive cell lines, including NA, which is
an EBV converted NPC-TW01 cell line [18], EVER8, which is a
cell line of 293 background with tetracycline inducible Rta and
Akata strain EBV [13], 293-Maxi, which is a 293 derivative cell
line harboring the EBV bacmid Maxi [19] and B22, which is a
tetracycline inducible BGLF4 expressing cell line. BGLF4 is
expressed at a similar level in these cell lines (Figure S1). Then
GFP-positive cells were selected by FACS. Consistent with our
previous studies, the S-phase cell population of gated GFP-
BGLF4-expressing cells increased by approximately 10%
(Figure 1A, left panels) [12]. We wondered whether differential
expression levels of BGLF4 may lead to different extents of
chromosome condensation. Therefore, the DNA contents of cells
with various BGLF4 expression levels were analyzed by FACS
according to the intensity of GFP fluorescence. Cells with high
GFP-BGLF4 expression levels had a salient increase (about 20%)
of S-phase DNA content, compared to those cells expressing GFP
or GFP-K102I (Figure 1A, middle panels). On the contrary, the S-
phase population of cells with low BGLF4 expression levels was
not obviously different from those expressing GFP or GFP-K102I
(Figure 1A, right panels), suggesting that cells with high BGLF4
expression levels accumulate in S-phase, while cells can proliferate
with moderate BGLF4 expression.
BGLF4 Interferes with Nascent Cellular DNA Synthesis
and Cell Cycle Progression
About 40% of cells with high BGLF4 expression levels
accumulate at S-phase (Figure 1A), which seems to be conflict
with the fact that BGLF4-mediated suppression of MCM4-
MCM6-MCM7 DNA helicase activity inhibits cellular DNA
replication. To monitor the effect of BGLF4 on DNA synthesis,
HeLa cells transfected with BGLF4 or K102I or vector plasmids
were subjected to a thymidine incorporation assay to measure
nascent DNA synthesis during 4 to 24 h post transfection
(Figure 1B). There was a BGLF4 dose-dependent decrease of
[
14C] thymidine incorporation in transfected cells, suggesting that
cellular DNA replication was repressed by BGLF4 expression,
especially cells with high BGLF4 expression.
To elucidate whether BGLF4 blocks or only delays the S-phase
progression, we checked the number of cells that can enter G2/M.
To this end, HeLa cells expressing GFP, GFP-BGLF4 or GFP-
K102I were treated with the microtubule assembly interfering
agent nocodazole (Noc) for 20 h at 24 h post transfection to arrest
cell cycle progression at the G2/M boundary (Figure 1C). Total
cells with protein expression as indicated were subjected to FACS
analysis. More than 50% of HeLa cells with GFP or GFP-K102I
expression reached 4 N DNA content after nocodazole treatment
at 44 h post transfection. On the contrary, most of the GFP-
BGLF4-expressing cells accumulated in G1 or S phase, indicating
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to reach the G2/M boundary in the presence of BGLF4
expression. Thus, the increase of the cell population with DNA
contents between 2N and 4N in Figure 1A could be an outcome of
the BGLF4-induced repressive effect on DNA synthesis. The
increased G1 population observed in Figure 1C may be due to the
additional 20 h of BGLF4 expression, suggesting BGLF4 also
interferes with G1/S transition. We suggest the suppression of
G1/S transition could be due to the blocking of MCM-helicase
activity, which is required for the initiation of DNA replication,
whereas the retardation of S phase progression may be caused by
BGLF4-induced premature chromosome condensation.
BGLF4 Cannot Compensate for Cdk Activity for S Phase
Progression in Temperature-sensitive Mutant Yeasts
Both BGLF4 and its homolog HCMV UL97 have been
reported recently to promote the budding of the temperature-
sensitive (ts) yeast cdc28-13 under asynchronous culture conditions
at the non-permissive temperature [15]. To determine whether
BGLF4 displays S-phase like Cdk activity in yeast, we monitored
the function of BGLF4 in the yeast system. The yeast cell cycle is
controlled by a single Cdk with various cyclin partners. Yeast Cdk
promotes bud emergence, spindle pole body duplication, DNA
replication, spindle formation and cell division [20]. Its homo-
logues in prokaryotic and mammalian cells have been identified
and proved to compensate the kinase activity in the ts mutant yeast
strain cdc28-4. Cdc28-4 is arrested at G2/M phase and shows
budded morphology at the non-permissive temperature [21]. The
other Cdk1 ts strain, cdc28-13, is appropriate for a budding assay
because it is arrested at G1 in a non-budded form at the non-
permissive temperature [21]. To determine further whether
BGLF4 can compensate for the Cdk defect in S. cerevisiae cdc28-
4, human Cdc2, BGLF4- or K102I-transformed cdc28-4 were
spotted onto YPD plates and cultured at the permissive (23 or
30uC) or non-permissive (38uC) temperature for 2 days. In contrast
to Cdc2-expressing yeasts, BGLF4- and K102I- expressing yeasts
did not grow at the non-permissive temperature, indicating that
BGLF4 could not provide the Cdc28 activity for cell cycle
progression in budding yeasts (Figure 2A and 2B). Similarly, UL97
could not compensate yeast Cdc28 activity in the compensation
assay (data not shown). Therefore we wondered whether BGLF4
Figure 1. BGLF4 induces the accumulation of the S-phase cell population and represses [
14C]-thymidine incorporation into HeLa
cells. (A) Asynchronous HeLa cells were seeded and transfected with GFP-BGLF4, GFP-K102I expressing plasmids or control GFP vector. At 24 h post
transfection, cells were harvested and stained with propidium iodide. The cell cycle profile was analyzed by FACS according to the GFP intensities (left
panels). Cells with high GFP expression (middle panels) were further subgrouped from GFP low cells (right panels). The statistics of cell cycle profiles
of GFP expressing cells were plotted. Cells with high GFP-BGLF4 expression showed significant accumulation in S-phase (middle panel). An asterisk (*)
indicates a statistically significant difference from vector control cells (P,0.05). Two independent experiments were performed and one of the results
is shown. (B) At 4 h post transfection, HeLa cells were labeled with [
14C]-thymidine for newly synthesized DNA. At 20 h post transfection, [
14C]-
thymidine was measured using a liquid scintillation counter. An asterisk (*) indicates a statistically significant difference from vector control cells
(P,0.05). Reproducible data were observed in at least three independent experiments. (C) The M-phase synchronous protocol for GFP-BGLF4 or GFP-
K102I expressing cells is indicated. HeLa cells were seeded and transfected with GFP-BGLF4, GFP-K102I or GFP vector expressing plasmids. At 24 h
post transfection, cells were treated with 200 ng/ml Nocodazole (Noc). After 20 h of Noc treatment, cells were harvested and stained with propidium
iodide. Cell cycle profiles of whole cell populations were analyzed by FACS. Two independent experiments were performed.
doi:10.1371/journal.pone.0039217.g001
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advances of bud emergence, as reported, but not DNA replication
in yeast. Indeed, bud growth is not absolutely coordinated with the
initiation of DNA replication [22]. To determine more precisely
whether BGLF4 can promote G1/S transition, we carried out the
yeast budding assay in cdc28-13 cells treated with hydroxyurea
(HU), which can block the DNA synthesis, ensuring that most of
the cells are in G1 phase. Compared to Cdc2- or UL97-expressing
yeast cells, bud growth of BGLF4-transformed yeast cells did not
burgeon after the release of non-permissive temperature (38uC)
(Figure 2C and 2D). We then analyzed the DNA content of cdc28-
13 cells with different kinases by FACS after HU treatment
(Figure 2E). After the treatment, over 80% of cdc28-13 cells were in
a non-budded form and arrested at the G1/S boundary. Although
HA-UL97 was immunoprecipitated by HA antibody less effec-
tively, leading to the kinase activity of UL97 being relatively
weaker in the IP-kinase reaction (Figure S2), the expression levels
of HA-BGLF4, HA-UL97 and HA-Cdc2 were similar in cdc28-13
cells (Figure 2D). Taken together, the data imply that BGLF4 has
kinase activity in yeast but cannot compensate for cdc28 activity
for cell growth, promoting yeast budding and S-phase progression.
Considering the previous study [15], we believe that the result here
is more conclusive because the yeast cells were synchronized
before the analysis. The data also are consistent with our
observation that BGLF4 activity resembles Cdk-1 activity rather
than Cdk-2 activity in mammalian cells.
Expression Level of BGLF4 is the Key Factor to Determine
Cell Fates
To elucidate the perturbation of cell cycle progression by
BGLF4 in the individual cell, we established a GFP-H2B-HeLa
cell line stably expressing GFP-H2B to monitor the BGLF4-
induced events in living cells. H2B is a component of core histone
octamers, which are packaged around the double stranded DNA
into the basic subunits of eukaryotic chromosomes. The chromo-
somes of living cells can be visualized through GFP-H2B
observation with fluorescence microscopy [23]. We found
DsRed-BGLF4, but not DsRed-K102I or DsRed, induced
chromosome condensation in GFP-H2B-HeLa cells at 24 h post
transfection. In addition, GFP-H2B signals colocalized with the
Hoechst 33258-stained DNA, suggesting that this is a good
indicator of the chromosome pattern in living cells (Figure 3A).
To identify the fate of individual cells with BGLF4 expression,
DsRed vector control or DsRed-BGLF4 expressing plasmid was
transfected into GFP-H2B-HeLa cells. Six hours post transfection,
fields of view were selected randomly and imaged using time-
lapsed fluorescence microscopy for 24 h to determine whether the
cells could grow and divide normally after recombinant protein
expression. As expected, cells transfected with DsRed vector could
complete mitosis (Figure 3B). On the contrary, chromosomes in
cells with high BGLF4 expression levels condensed severely,
aggregated and eventually became puckered (Figure 3D), while
chromosomes in cells with low BGLF4 expression showed a
punctuate or loose condensation pattern and could segregate into
two daughter cells (Figure 3C). Only cells expressing low levels of
BGLF4 completed cytokinesis (32 out of 103 BGLF4 expressing
cells). According to the appearance of condensed chromosomes up
to the separation of two daughter cells, the cells with low BGLF4
expression spent a longer period of time in mitosis (about 80 min)
than control cells (about 60 min) while completing cytokinesis,
suggesting the G2/M checkpoint could be activated. Taken
together, we propose that BGLF4 expression levels are critical in
determining cell fates.
Expression of BGLF4 in 293 T-REx and TW01 T-REx BGLF4
Inducible Cells Leads to Growth Retardation
To observe the long-term effects of BGLF4 on cell growth,
BGLF4 inducible cells were established in a 293 tetracycline-
regulated expression system (293 T-REx). In the following studies,
clone V4 carrying vector, clones B9, B10, B17, B19, B20 and B22
carrying BGLF4, or clone K9 carrying K102I were selected to
determine their protein expression levels as detected by immuno-
blotting and indirect immunofluorescence assays (Figure S3A and
S3C). BGLF4 could be detected at 3 h post induction (hpi) and
persisted for at least 120 hpi in B22 cells (Figure S3B). The
premature chromosome condensation phenomenon induced by
BGLF4 was observed at 6 hpi, accompanied by its nuclear
distribution (Figure S3D), indicating that BGLF4 is biologically
functional in this model. BGLF4 expression levels in B22 cells were
also compared to reactivated EBV positive cells to verify
comparable levels of BGLF4 expression in this system (Figure S1).
To determine whether BGLF4 affects cell proliferation, V4, B22
and K9 cells were induced with doxycycline (Dox, 100 ng/ml) and
assessed for cell proliferation by MTT assay every 24 h until 120
hpi. Compared to V4 and K9 cells, B22 cells exhibited cell growth
retardation following Dox induction (Figure 4A). At 120 hpi, the
percentage of cell proliferation reduced to about 30% (P,0.01) in
B22 cells (the conversion equation is described in materials and
methods). This phenomenon also could be observed in the other
293 T-REx BGLF4 inducible cell lines, B9 and B20, after Dox
induction (Figure S3E). In the case of these two cell lines, the cell
proliferation was reduced to about 30% and 35%, respectively. To
explore further whether BGLF4 can affect the growth of NPC
cells, the tetracycline-regulated expression system also was
established in NPC-TW01 cells. VIT7 carrying vector, KIT2
and KIT21 carrying BGLF4 were selected according to the
protein expression levels detected by immunoblotting and
immunofluorescence assays (Figure S4A and S4C). Similar to
B22, BGLF4 could be detected at 3 h post induction, and persisted
for at least 120 hpi in KIT2 (Figure S4B). Also, the cell growth was
examined in the NPC-TW01 cell background. Both KIT2 and
KIT21 grew slower than VIT7 cells (Figure 4B). The cell
proliferation rate decreased to about 24% and 19% respectively.
Nevertheless, in both the 293 and TW01 cell background, cells
expressing BGLF4 can still grow continuously. Considering the
effect of BGLF4 on inducing prophase-like chromosome conden-
sation, it is possible that some cells may proliferate with damaged
DNA.
BGLF4 Elicits Genomic Instability in 293 and NPC-TW01
Cells
Micronuclei (MN) represent unincorporated chromosomal
fragments lost during sister chromatid segregation in mitosis and
are a common indicator for evaluating genomic instability [24].
Repetitive reactivations of EBV have been considered recently to
promote MN formation and tumor progression in NPC cells [6].
In addition, premature chromosome condensation induced by
calyculin A, which is a Ser/Thr phosphatase types 1 and 2A
inhibitor, was found prone to chromosomal breaks at common
fragile sites [25]. Therefore, we suggest BGLF4-expressing cells
may proliferate with damaged DNA and genomic instability. To
this end, we observed the chromosome pattern of DsRed-BGLF4-
transfected GFP-H2B-HeLa cells at 48 h post transfection and
found the formation of framework-shaped chromosome structure
(Figure 5A), implying that cells suffering BGLF4-induced chro-
mosome condensation might undergo further chromosomal
alterations. Since we did not observe similar patterns at 72 h post
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some abnormalities may die eventually.
Subsequently, micronucleus (MN) formation was examined in
293 T-REx B22, K9 and V4 cells after Dox induction for 72 h.
After induction, BGLF4 enhanced MN formation in 293 T-REx
B22 (Figure 5B), implying that persistent expression of BGLF4
elicits genomic instability. Compared to vector control cells and
K9 cells, the MN formation also was increased in non-induced
B22 cells. We suspected that there might be a very small amount of
BGLF4 expressed in B22 cells before induction (Figure S3A),
leading to the increase of MN. Notably, the MN occurrence in
BGLF4 expressing NPC-TW01 cells (13.03%) was much more
obvious than that in control cells (5.97%, P,0.01) (Figure 5C). In
addition to MN, donut-shaped, new moon-shaped, horse’s hoof-
shaped and other irregular chromosome patterns (37.08%) were
observed in KIT2 cells after Dox induction for 72 h, while the
Figure 2. BGLF4 cannot compensate for the kinase activity of Cdk1 for DNA replication in S. cerevisiae. (A) Five-fold serial dilutions of
cdc28-4 mutant yeasts containing pVT-U101 vector, BGLF4, K102I, or HA-Cdc2 expressing plasmids were spotted onto YPD plates and incubated at
23uC, 30uCo r3 7 uC for 2 days to observe colony growth. (B) The protein expression levels of BGLF4, K102I and Cdc2 in (A) were detected by
immunoblotting. The blot was detected with anti-BGLF4 and anti-HA antibody. (C) Saturated cdc28-13 cells carrying indicated plasmids were treated
with 0.2 M hydroxyurea (HU) at 23uC for 3 h to synchronize transformed yeast cells at an early stage of S-phase. The synchronized cells were released
into fresh YPD medium and incubated at the restrictive temperature for 4 h. The percentages of budded cells were determined at the time of
temperature shift and 4 h later. The asterisk (*) indicates a statistically significant difference from vector control cells (P,0.01). (D) Total cell extracts of
cdc28-13 transformed with pVTU vector, HA-BGLF4, HA-UL97 or HA-Cdc2 were harvested before and after HU release and subjected to
immunoblotting with HA antibody. (E) Asynchro, synchronized or released cdc28-13 cells containing the plasmids indicated were fixed and stained
with propidium iodide to analyze DNA contents by FACS.
doi:10.1371/journal.pone.0039217.g002
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only one-third (13.99%) of that in KIT2 cells (data not shown). We
examined two other BGLF4 inducible clones (KIT20 and KIT21).
MN formation and abnormal chromosomal structure also can be
observed at 60 hpi (data not shown). Taken together, these results
suggest that BGLF4 elicits genomic instability more severely in
NPC cells than in 293 cells.
The G1/S Transition Regulator RB is
Hyperphosphorylated but the RB-E2F1 Complex is not
Disrupted in the Presence of BGLF4
Our data above indicate that BGLF4 does not promote S-phase
progression. We noticed that in a previous study, only RB
phosphorylation, but not the downstream E2F1 transactivation
activity, was monitored in the presence of BGLF4 [15]. Therefore,
we decided to clarify the RB phosphorylation pattern and its
downstream signaling in cells expressing BGLF4. RB is known for
its essential role in sequestering E2F1through a distinct pocket
domain, resulting in inhibition of E2F transcription activity
[26,27]. RB is sequentially phosphorylated by cyclin-Cdks in a
cell cycle dependent manner [28,29]. The hyperphosphorylated
form of RB dissociates the RB-E2F1 complex, allowing E2F1
downstream genes required for DNA synthesis and G1/S
transition to be transcribed [30]. There are 16 Cdk-consensus
sites within RB. Ser780 has been shown to be a critical residue for
the subsequent hyperphosphorylation of multiple sites at the C-
terminus and disruption the RB-E2F1 complex [31,32]. Ser608
and Ser612 within the spacer domain are also required for the
disruption of the interaction at G1/S transition [32].
Nevertheless, RB is alternatively phosphorylated with different
patterns under different signaling situations. Ser612 is phosphor-
ylated by Chk1/2 in response to DNA damage, leading to a
complex stabilization between RB and E2F1 [33]. As a result,
phosphorylation of RB at different sites by various kinases may
result in different functions. Hyperphosphorylated forms of RB
were observed in EBV-positive cells. Both the phosphorylation on
Ser612 and Ser780 increased after EBV reactivation [4]. In
addition, RB was shown to be hyperphosphorylated in response to
the ectopic expression of BGLF4 and other CHPKs, including
HCMV UL97 [15].We wondered the BGLF4-induced RB
hyperphosphorylation could be a response to DNA damage
singling but not for DNA replication. To this end, we first
examined the RB phosphorylation pattern in EBV-positive Akata
(Figure 6A) and NA cells (data not shown) upon reactivation.
Consistent with the previous observation [4], the increase of
phosphorylation of total RB and Ser780 was not so obvious, while
phosphorylation on Ser612 was elevated during lytic virus
Figure 3. The BGLF4 expression level is the key factor that determines cell fates. (A) Slide-cultured GFP-H2B-HeLa cells were transfected
with DsRed-BGLF4, DsRed-K102I and DsRed-monomer. At 24 h post transfection, cells were fixed with 4% paraformaldehyde, stained for DNA using
Hoechst 33258 and examined using fluorescence microscopy. (B)(C)(D) GFP-H2B-HeLa cells were seeded and transfected with (B) DsRed-monomer
vector or (C)(D) Ds-Red-BGLF4. At 6 h post transfection, fields of view were selected randomly and filmed using an Axiovert 200 M inverted
fluorescence microscope every 10 min.
doi:10.1371/journal.pone.0039217.g003
EBV BGLF4 Kinase Retards S-Phase Progression
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39217replication, accompanied by the expression of BGLF4 in Akata
cells (Figure 6A).
To investigate the effects of BGLF4 on hyperphosphorylation of
RB, RB-deficient Saos-2 cells were transfected with plasmids
expressing BGLF4, K102I, or vector along with an RB expressing
plasmid. HMCV UL97 was added to the experiment as a
comparison for RB hyperphosphorylation [15,34]. In contrast to
K102I or vector transfected cells, cells expressing BGLF4, as well
as UL97, showed a band-shift hyperphosphorylated RB (Figure 6B)
and increased phosphorylation on Ser780, as reported previously
[15]. To elucidate the effect of RB phosphorylation on the stability
of the RB-E2F1 complex, an immunoprecipitation assay was
performed with anti-RB antibody and the immunocomplexes were
detected with anti-RB and anti-E2F1 antibodies. Throughout
several repeated experiments, weak but consistent results were
observed that the amount of E2F1 co-precipitated with anti-RB
antibody in the presence of BGLF4 expression was not obviously
different (Figure 6C). We assumed the RB phosphorylation pattern
observed here does not contribute to cell cycle progression. To
support this hypothesis, the promoter activity of the E2F1
downstream gene cyclin D1 (p-CCND-luc, which contains a
3.3 kb promoter region of cyclin D1) was examined in a reporter
assay (Figure 6D). Cyclin D1 promoter activity was enhanced by
E2F1 alone and suppressed when RB was co-transfected with
E2F1. Upon ectopic BGLF4 expression, the RB-inhibited cyclin
D1 promoter activity was suppressed further. Furthermore,
BGLF4 had a dose-dependent effect on the down-regulation of
cyclin D1 promoter activity and the hyperphosphorylation of RB
(Figure 6D), suggesting that expression of BGLF4 does not favor
cell cycle progression. This observation implies that, in addition to
Figure 4. Expression of BGLF4 results in slight cell growth retardation. (A) 293 T-REx BGLF4 inducible B22, K102I kinase dead K9 and vector
control V4 cells were seeded into 96-well plates in triplicate and incubated in 100 ng/ml Dox containing medium to induce the expression of BGLF4
or K102I. At 24, 48, 72, 96 and 120 h post induction (hpi), MTT assays were performed and the optical densities (OD) were determined by
spectrophotometry at 550 nm. Three independent experiments were conducted and one representative result is shown. (B) NPC-TW01 T-REx BGLF4
inducible KIT2, KIT21 cells and vector control VIT7 cells were induced with 50 ng/ml Dox and subjected to an MTT assay as described in (A).
doi:10.1371/journal.pone.0039217.g004
EBV BGLF4 Kinase Retards S-Phase Progression
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39217Ser780, at which phosphorylation is required for E2F1 dissociation
from RB, BGLF4 may also induce phosphorylation at other
residues, to affect RB-downstream signaling.
We then elucidated whether BGLF4-elicited RB phosphoryla-
tion is a downstream effect of DDR. We generated RB Ser612 and
Ser780 phosphorylation mutants and used phospho-specific
antibodies to determine whether BGLF4 enhances the phosphor-
ylation on RB Ser612 (Figure 6E). Although the phosphorylation
on Ser780 was more obvious than that on Ser612 of wild-type RB
(lanes 1 and 2), we noticed that the BGLF4-induced RB band shift
was reduced in S612A but not in S780A (lanes 3 and 4, lanes 5
and 6), implying that Ser612 may be a major target of BGLF4. It is
worthy of note that BGLF4 also led to RB phosphorylation on
Ser612, even though Chk2 was not obviously activated under this
condition, suggesting that BGLF4 has the potential to phosphor-
ylate RB directly at Ser612. We then examined the promoter
activity of ZBRK1, a transcription factor negatively regulated by
the RB-E2F1 complex at the transcription level upon DDR [35].
ZBRK1 promoter activity was slightly down-regulated when RB
and E2F1 were co-expressed in Saos-2 cells (Figure 6F). In the
presence of BGLF4, the ZBRK1 promoter activity was suppressed
further in a dose dependent manner (Figure 6F), implying that
BGLF4-elicited RB hyperphosphorylation is in response to DNA
damage signaling but not for cell cycle progression.
Discussion
BGLF4 is a member of the conserved herpes protein kinases
(CHPKs), which are known to mimic cellular Cdk activities but are
not restrained by Cdk inhibitors [10,12]. BGLF4 induces multiple
mitotic-like events [12,13], induces RB hyperphosphorylation [15]
and elicits DDR [17] in a cell cycle-independent manner. These
changes triggered by BGLF4 appear to be contradictory in terms
of cell cycle control. Here we have shown BGLF4 interferes with
DNA replication and S-phase progression, restraining cells from
entering G2/M phase. Observation of individual BGLF4 express-
ing cells using time-lapse microscopy supports this finding. Once
BGLF4 induces highly condensed chromosomal structures, cells
cannot complete the cell cycle. Nevertheless, cells with moderate
BGLF4 expression still went through cytokinesis with a time delay.
To avoid the influence of endogenous Cdk activity, we used a
temperature-sensitive yeast system to determine whether BGLF4
promotes S-phase progression. BGLF4 could not promote bud
growth or S-phase progression of the cdc28-13 strain synchronized
Figure 5. Expression of BGLF4 elicits abnormal chromosomal structure and micronuclei formation in various cell types. (A) Slide-
cultured HeLa cells with stable GFP-H2B expression were transfected with DsRed-BGLF4, DsRed-K102I or pDsRed-monomer. At 48 h or 72 h post
transfection, cells were fixed, stained for DNA with Hoechst 33258 and examined using fluorescence microscopy. (B) Slide-cultured 293 T-REx B22, K9,
and V4 cells were treated with 100 ng/ml doxycycline (Dox). At 72 h post induction (hpi), cells were fixed with 4% paraformaldehyde and stained for
DNA with Hoechst 33258. Micronucleus (MN) formation was observed using fluorescence microscopy. Detection of MN formation (MN%) was
calculated as the percentage of cells containing micronuclei, derived from the analysis of 1,000 cells. Bars represent mean values in MN%
(duplicates6SD). One of the two independent experiments conducted is shown. (C) Slide-cultured NPC-TW01 T-REx KIT2 and VIT7 cells were
incubated with 50 ng/ml Dox for 72 h. Cells were fixed with 4% paraformaldehyde and examined using fluorescence microscopy. Detection of MN
formation (MN%) was calculated as the percentage of cells containing micronuclei, derived from the analysis of 1,200-1,600 cells. An asterisk (*)
indicates a statistically significant difference from vector control cells (P,0.01). One of the two independent experiments conducted is shown.
doi:10.1371/journal.pone.0039217.g005
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like Cdk1 than Cdk2. On investigating the G1/S transition
regulator, RB, we found that, although RB was hyperpho-
sphorylated in the presence of BGLF4, the RB-E2F1 complex did
not dissociate. The reporter assays further demonstrate that
BGLF4 induced a dose-dependent suppression of E2F1 down-
stream cyclin D1 and ZBRK1 promoter activities.
Recently, it was shown in the fission yeast model that the cell
cycle can be driven by oscillation of a minimal Cdk control
network lacking canonical regulation such as CAK (Cdk activating
kinase) and Cdk inhibitors [36]. It was proposed that the Cdk
oscillator acts as the primary organizer of the cell cycle by setting
two thresholds of Cdk activity to define independent cell cycle
phases. Notably, G1/S and G2/M transitions are associated with
low and high Cdk activities, respectively. This model supports our
data regarding BGLF4 mediated S-phase disturbance, because
BGLF4 resembles constitutive Cdk activities throughout the cell
cycle.
Uncoordinated RB hyperphosphorylation and cell cycle pro-
gression upon EBV reactivation also was reported in another
study. In this condition, RB was hyperphosphorylated because of
the elevated expression of S-phase cyclins and upregulated S-Cdk
Figure 6. RB is hyperphosphorylated but the RB-E2F1 complex is not disrupted in the presence of BGLF4. (A) EBV-positive Akata cells
were induced by 0.8% anti-human IgG and harvested at the time points indicated. The proteins were resolved by 7.5% SDS-PAGE (for total RB) or 10%
SDS-PAGE (for RB specific phosphorylation, Zta, BGLF4 and GAPDH). Zta and BGLF4 were detected to confirm lytic cycle progression. GAPDH served
as a loading control. (B) Saos-2 cells were transfected with the expressing plasmids indicated. Cells were harvested at 24 h post transfection. The
protein expression levels were resolved by 7.5% SDS-PAGE (for RB) or 10% SDS-PAGE (for BGLF4, HCMV UL97, RB specific phosphorylation and
GAPDH). GAPDH served as a loading control. (C) Saos-2 cells were transfected with the plasmids indicated. Cells were harvested at 24 h post
transfection and cell extracts were subjected to immunoprecipitation assays using anti-RB antibody. The immunocomplexes were separated by 10%
SDS-PAGE. The co-immunoprecipitated proteins RB and E2F1 were detected using specific antibodies. (D) Luciferase reporter assays were performed
in Saos-2 cells by co-transfected with p-CCND1-luc (a 3.3-kb full length cyclin D1 promoter construct) as well as pWP1 (for normalization of
transfection efficiency) and plasmids of effectors as indicated. Luciferase activities were measured at 48 h post transfection. Results are means 6 SD
from three separate transfections. Data are representative of two independent experiments. (E) Saos-2 cells were transfected with the expression
plasmids as indicated. Cells were harvested at 48 h post transfection. The protein expression levels were resolved by 7.5% SDS-PAGE (for RB) or 10%
SDS-PAGE (for BGLF4, Chk2, RB specific phosphorylation and b-actin). b-actin served as a loading control. (F) Luciferase reporter assays were
performed in Saos-2 cells by co-transfection of p-ZBRK1-luc (containing ZBRK1 promoter fragment -624 to +47 bp) as well as pWP1 (for normalization
of transfection efficiency), and plasmids of effectors as indicated in the figure. Luciferase activities were measured at 48 h post transfection. Results
are means 6 SD from two separate transfections. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0039217.g006
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blocked [4]. It is interesting to note that phosphorylation of RB on
Ser612 increased more dramatically than on Ser780, following
EBV reactivation. The phosphorylation on Ser780 even decreases
slightly at 72 hpi [4]. Here, we also demonstrate similar RB
phosphorylation patterns in EBV positive Akata (Figure 6A) and
NA (data not shown) cells after lytic cycle reactivation. Overall, a
hypothetical model is proposed to illustrate the effects of BGLF4
on RB phosphorylation and cell cycle progression in cells
replicating the virus (Figure 7). BGLF4 is expressed with an
early-late kinetic pattern, its expression starting at an early stage of
replication and increasing after viral DNA replication. We suggest
that at the early stage, low concentrations of BGLF4 do not affect
the host cell cycle but are sufficient to enhance the transactivation
activity of Zta and the synergistic activation of BMRF1 and Zta on
the BHLF1 promoter within the lytic origin of replication (oriLyt)
[37]. Along with the progression of viral DNA replication, BGLF4
expression reaches the maximal level and induces premature
chromosome condensation and arrest of cellular DNA synthesis. A
subset of cells may proliferate with abnormal DNA structure.
Phosphorylation of RB on Ser612 but not Ser780 was more
obvious at a later stage of the lytic cycle, suggesting it as a
downstream effect of EBV-elicited DDR in the cells (Figure 6 A).
Alternatively, BGLF4 may activate TIP60 histone acetyltransfer-
ase and induce the ATM-mediated DDR pathway, leading to the
phosphorylation of RB on Ser612 [17]. Because Chk2 was not
significantly activated in Saos-2 cells in our experiments, it is very
likely that Ser612Pro613 of RB can be phosphorylated directly by
BGLF4. This conclusion is supported by the observation that the
increase of RB Ser612 phosphorylation at a later stage of the lytic
cycle (48 h post induction) is correlated with higher BGLF4
expression. Because the DNA damage pathway is necessary for
efficient EBV replication, we proposed that BGLF4-induced RB
phosphorylation is favorable for lytic cycle progression, while
cellular DNA synthesis is blocked.
Uncontrolled and constitutive Cdk activities may contribute to
unscheduled proliferation, as well as genomic instability (GIN) and
chromosomal instability (CIN), because switch-off of Cdk1-like
activity is required for correct sister chromatid separation,
chromosome decondensation, nuclear envelope reformation and
cytokinesis [38,39]. Therefore, deregulation of Cdk1 activity and
the consequent deregulated function of Cdk1 substrates may
contribute to abnormal genome organization [39]. In this study,
we used BGLF4-inducible 293 and NPC-TW01 cells to observe
the long-term effects of BGLF4 on chromosome structures. In
addition to MN formation, BGLF4 elicits abnormal chromosome
structure, particularly in NPC-TW01 cells. Several aspects of
BGLF4 function may contribute to genomic instability. In our
previous studies, BGLF4 was shown to induce some mitosis-like
events, including premature chromosome condensation, through
topoisomerase II (Topo II) activation and nuclear lamina
disassembly through lamin A/C phosphorylation. Under physio-
logical conditions, these events are tightly controlled in a cell-cycle
dependent manner and occur only in M-phase. Topo II is a
ubiquitous enzyme regulating DNA topology through a transient
double-stranded break. As a result, Topo II functions like a
‘‘double-edged sword’’, being essential for cells but potentially
genotoxic at a high level of protein expression. With abnormally
high levels of Topo II, double-stranded breaks may become
permanent, leading to chromosomal translocation and other DNA
aberrations [40]. Indeed, increased levels of Topo II are associated
with mixed lineage leukemia (MLL) [41,42] and breast cancer
[43]. On the other hand, lamin A/C is the component of nuclear
lamina, constituting a supporting meshwork to maintain nuclear
structure. The integrity of lamina is crucial to nuclear stiffness and
the spherical shape of nuclei [44]. BGLF4 phosphorylates lamin A
at amino acids 22, 390, 392, 652 and 657, leading to the
disassembly and reorganization of the nuclear lamina [13]. As a
result, BGLF4 may elicit CIN at the nuclear structure level, too.
Furthermore, it is speculated that premature chromosome
condensation induces chromosome breaks at common fragile site
[25], reinforcing the linkage of BGLF4 and CIN. Thus, BGLF4
may be one of the important factors that mediate recurrent,
reactivation-induced genomic instability in EBV positive NPC
cells [6]. Here, we showed that BGLF4 may be involved in
multiple pathways leading to GIN, suggesting that BGLF4 may
play a role in EBV-associated epithelial tumor progression.
Materials and Methods
Plasmids
pYPW17 and pYPW20 are pSG5 (Promega) based plasmids
which express BGLF4 and K102I, as described previously [45].
To generate the tetracycline regulated expression plasmids
pLenti4-BGLF4 and pLenti4-K102I, a DNA fragment of BGLF4
open reading frame 1-1290 with RsrII restriction enzyme sites at
both ends was PCR amplified using pYPW17 or pYPW20 as
template and forward primer LMRC481 (59-CACGGTCCGAC-
CATGGATGTGAATATGGCTGC-39) and reverse LMRC482
(59-CACGGACCGTCATCCACGTCGGCCATCT-39). The
Figure 7. A hypothetical model of BGLF4-induced RB phosphorylation and DNA damage response (DDR). BGLF4 induces premature
chromosome condensation through activation of condensin and Topo II. The prophase-like chromosomes may cause abnormal DNA structure and
micronucleus formation. In addition, BGLF4 elicits DNA damage signaling by phosphorylating TIP60. TIP60 is a histone acetyltransferase that
regulates chromatin remodeling and the DNA damage response (DDR). Upon DNA double-stranded breakage, ATM kinase is acetylated by TIP60. The
acetylation of ATM is essential for its autophosphorylation and activation. Therefore, BGLF4 is able to turn on DNA damage signaling in a TIP60/Chk2-
dependent manner. Here we found that the exogenous expression of BGLF4 induces RB hyperphosphorylation at Ser780 and Ser612, which is an
indicator of DNA damage signaling activation. Based on our observation that the RB-E2F1 complex does not dissociate and the E2F1-downstream
cyclin D1 promoter and ZBRK1 activities are repressed upon BGLF4 expression, we propose that BGLF4-induced RB phosphorylation may be a
downstream event of DDR. Because the DNA damage pathway is necessary for efficient EBV replication, BGLF4-induced RB phosphorylation is
favorable for lytic cycle progression, while cellular DNA synthesis is blocked.
doi:10.1371/journal.pone.0039217.g007
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site of pLenti4-TO-V5-His (Invitrogen). pCPL4 and pTHL5 are
plasmids expressing GFP-BGLF4 and GFP-K102I, generated by
cloning a BamHI-EBV BGLF4-EcoRI fragment from pYPW17 or
pYPW20 into the BglII-EcoRI cloning site of pEGFP-c1 (BD
Biosciences). pYHC3 and pYHC4 are plasmids expressing DsRed-
BGLF4 and DsRed-K102I, generated by cloning the BamHI-
BGLF4-BglII fragments from pYPW17 and pYPW20 into the
BamHI site of pDsRed-monomer-c1 (Clonetech). CMV-NeoRB,
which contains pRB cDNA in pCMV-neo-Bam, was kindly
provided by Dr. Phang-Lang Chen (Department of Biological
Chemistry, University of California, Irvine, CA) [46]. For RB
phosphorylation mutants, RB-S612A and RB-S780A were gener-
ated by a single-primer-based site-directed mutagenesis strategy
using CMV-NeoRB as template and forward primer LMRC855
(tatgtatctttctcctgtaagagctccaaagaaaaaaggttcaac) or LMRC856
(tccaccaggccccctaccttggcaccaatacctcacattcctc) respectively.
pCMV-E2F1 was a gift from Dr. Sheau-Yann Shieh (Institute of
Biomedical Sciences, Academia Sinica, Taiwan) [47]. CCND1
reporter plasmids (CCND1-P) containing the 3.3-kb cyclin D1
promoter, and ZBRK1 reporter plasmids (ZBRK1-B) containing
ZBRK1 promoter fragment -624 to +47 bp, were a gift from Dr.
Ju-Ming Wang (Institute of Basic Medical Sciences, National
Cheng Kung University, Taiwan) [35]. pEGFP-H2B, which
expresses a GFP-H2B fusion protein, was generously provided
by Dr. Zee-Fen Chang (Institute of Biochemistry and Molecular
Biology, National Yang-Ming University, Taiwan).
Cell Culture and Transfection
HeLa cells (ATCC: CCL-2), derived from a human cervical
carcinoma, were grown in Dulbecco’s modified Eagle’s medium
(DMEM) with 8% fetal calf serum. Saos-2 (ATCC: HTB-85), an
RB deficient cell line derived from a human primary osteosarco-
ma, was grown in DMEM medium with 8% fetal calf serum. 293
T-REx cell line (Invitrogen) is a HEK293 derivative containing a
Tet repressor. NPC-TW01 was derived from an EBV-negative
human nasopharyngeal carcinoma [48]. Cells were transfected
using Lipofectamine 2000 (Invitrogen) in OptiMEM medium
(GIBCO-BRL) according to the manufacturer’s instructions.
TW01 T-REx cells stably expressing the Tet repressor were
generated using the ViraPower T-REx lentiviral expression system
(Invitrogen). 293 T-REx and TW01 T-REx cell lines were grown
in DMEM medium with 8% tetracycline-free fetal calf serum. To
establish tetracycline-regulated BGLF4 inducible cell lines, 293 T-
REx or TW01 T-REx cells were transfected with pLenti4,
pLenti4-BGLF4 or pLenti4-K102I and selected with zeocin
(400 mg/ml for 293 T-REx or 500 mg/ml for TW01 T-REx)
and blasticidin (5 mg/ml for 293 T-REx or 25 mg/ml for TW01 T-
REx) for two months. The V4 clone carrying vector, B9, B10, B17,
B19, B20 and B22 clones carrying the BGLF4 expression plasmid
and K9 clone carrying the K102I expression plasmid were selected
from 293T-Rex cells. The VIT7 clone carrying vector, as well as
KIT2 and KIT21 carrying the BGLF4 expression plasmid, were
picked out from TW01 T-REx for further studies. The selected
clones were maintained in the presence of zeocin (200 mg/ml for
293 T-REx or 250 mg/ml for TW01 T-REx) and blasticidin
(2.5 mg/ml for 293 T-REx or 12.5 mg/ml for TW01 T-REx). To
induce protein expression, doxycycline (Dox) was added (100 ng/
ml for 293 T-REx or 50 ng/ml for TW01 T-REx) to the culture
medium. The inducibility and positive rate of BGLF4 in individual
clones were examined by immunoblotting and indirect immuno-
fluorescence assay (IFA) after Dox treatment for 24 h. The
induction rates of both cell lines were more than 95%, as revealed
by IFA. To establish HeLa cells stably expressing GFP-H2B (GFP-
H2B-HeLa), HeLa cells were transfected with a GFP-H2B
expression plasmid and selected with G418 (1 mg/ml) for 1
month. The clone 3A1 with more than 95% GFP-H2B positive
cells in IFA was used for further experiments. All cells were
maintained in the presence of 1 mM L-glutamine and penicillin
(100 U/ml) and streptomycin (100 mg/ml) at 37uC with 5% CO2.
Akata cell line with recombinant EBV [49] that expressed
enhanced green fluorescent protein was grown in RPMI 1640
medium with 8% fetal calf serum and reactivated with 0.8% anti-
human IgG.
Cell Cycle Synchronization and Fluorescence-activated
Cell Sorter (FACS) Analysis
GFP-BGLF4-transfected HeLa cells were treated with nocoda-
zole (200 ng/ml) for 20 h at 24 h post transfection to arrest them
at the G2/M boundary. After synchronization, cells were
trypsinized, washed with PBS, fixed with 1% paraformaldehyde
at room temperature for 20 min and then with 75% ice-cold
ethanol overnight. Before FACS analysis, cells were permeabilized
with 0.2% Triton X-100 and RNase A (100 ng/ml) and DNA was
stained with propidium iodide (10 mg/ml) at room temperature for
30 min. Finally, cell cycle distribution according to DNA contents
was determined using a FACSCalibur cell sorter and analyzed by
CellQuest software (BD Biosciences).
Thymidine Incorporation Assay
HeLa cells were seeded in 6-well plates (3610
5/well) and
transfected with BGLF4, K102I expressing plasmid or vector. At
4 h post transfection, cells were labeled with [
14C]-thymidine
(0.05 mCi/ml) for 20 h. Subsequently, cells were trypsinized,
washed with PBS and lysed in 0.8 ml 0.2N NaOH. Half of the
NaOH lysates was added to 4 ml Ready-safe liquid scintillation
liquid (Beckman Coulter) and counted in a liquid scintillation
analyzer (LS 6000 TA, Beckman Coulter).
Immunoblotting and Co-immunoprecipitation
Cell extracts harvested with NP-40 lysis buffer (1% NP-40,
50 mM Tris, pH 8.0, 150 mM NaCl, 2 mM EDTA, and 1 mM
Na3VO4) were resolved by SDS-polyacrylamide gel electrophore-
sis (7.5% acrylamide gel for RB detection or 10% acrylamide gel
for the detection of other proteins). After transfer and blocking, the
primary antibodies used were Zta mAb (1B4) [50], BGLF4 mAb
(2616) [45], GAPDH mAb (Biodesign), a-tubulin mAb (Calbio-
chem), b-actin mAb (AC-15, Sigma), RB mAb (pMG3-245, kindly
provided by Dr. Wen-Hwa Lee (Department of Biological
Chemistry, University of California, Irvine, CA)), phosphoPlus-
RB Ab Kit (#9969, Cell Signaling), RB p-Ser612 mAb (4E4,
Abnova), Chk2 (H-300, Santa Cruz), Chk2 p-Thr68 (#2661, Cell
Signaling) and E2F1 Ab (C-20, Santa Cruz). To perform co-
immunoprecipitation assays, 600 mg of Saos-2 cell extract was
prepared in NP-40 lysis buffer and pre-cleared with 100 ml of 20%
protein A-Sepharose beads (Pharmacia) for 1.5 h at 4uC. To
immunoprecipitate RB-associated E2F1, 500 mg of lysates pre-
pared above were incubated with anti-RB antibody at 4uC
overnight. Then 150 ml of 20% protein A-Sepharose beads were
added to pull down the immunocomplexes for 3 h at 4uC. The
beads were washed with NP-40 lysis buffer four times and
resuspended in 4X SDS sample buffer. The immunocomplexes
were resolved in 10% SDS-PAGE and analyzed with immuno-
blotting using anti-RB and anti-E2F1 antibodies.
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S. cerevisiae cdc28-4 [21] and cdc28-13 [21] were gifts from Dr.
Curt Wittenberg (Department of Molecular Biology, The Scripps
Research Institute, CA). Both strains were cultured in YPD (1.0%
yeast extract, 2.0% bacto peptone, 20% glucose) medium.
pVTU101 (from Dr. Shu-Chun Teng, Graduate Institute and
Department of Microbiology, National Taiwan University) based
plasmids expressing BGLF4, K102I, HA-Cdc2 and UL97
(pMTS1, pMTS2, pMTS3 and pMTS4) were generated by
cloning a BamHI-BGLF4 fragment from pYPW17, BamHI-
K102I fragment from pYPW20, XbaI-HA-Cdc2 fragment
partially digested from pSMcdc2H-HATag (a gift from Dr. David
Morgan (Department of Physiology and Biochemistry, University
of California, San Francisco, CA), and a HindIII/XbaI fragment
of HCMV UL97 from pTAG-UL97. pMTS5 and pMTS7 are
constructs expressing HA-tagged BGLF4 and UL97, generated by
inserting an HA linker into the BamHI site of pMTS1 and HindIII
site of pMTS4.
Spot Dilution Assay
S. cerevisiae cdc28-4 cells containing various plasmids as indicated
were adjusted to an OD600 to 0.5, and diluted serially 5-fold in
sterile water. Two ml of each dilution were spotted onto YPD
plates. The plates were incubated at 23, 30 or 37uC for 2 days.
Yeast Budding Assay and FACS Analysis
S. cerevisiae cdc28-13 cells were grown at 23uC in SC medium
(0.17% yeast nitrogen base without amino acids, 0.5% ammonium
sulfate, 0.2% amino acid drop-out mix, 20% dextrose) and lacking
uracil to 0.5 OD at 600 nm. Hydroxyurea (HU, 200 mM) was
added into the culture medium and incubated at 23uC for 3 h.
Then, cells were collected and quickly resuspended in fresh YPD
medium without HU at 38uC for 4 h. For budding assays, cells
were fixed in 3.7% (vol/vol) formaldehyde at 4uC overnight. Cell
aggregates were sonicated and counted under phase contrast
microscopy (Axioskop 49 FL, Zeiss) for the percentage of budded
cells. Before FACS analysis, 10
7 yeast cells were fixed in 70%
ethanol at 220uC overnight, washed with PBS and treated with
50 mM Tris-HCl containing RNase A (100 mg/ml) at 37uC for
1 h. Cells were stained with 10 mg/ml PI (propidium iodide) at
4uC overnight and the DNA contents were then analyzed by flow
cytometry.
Indirect Immunofluorescence Assay
At the time points indicated post transfection or induction, slide-
cultured cells were fixed with 4% paraformaldehyde at room
temperature for 20 min and washed with PBS for 5 min. Cells
were permeabilized with 0.1% Triton X-100 for 5 min and
subjected to immunofluorescence staining. Cells were first stained
with anti-BGLF4 mAb (2224) at 37uC for 1.5 h, followed by
fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin
G (IgG) (Jackson) or rhodamine red-conjugated anti-mouse IgG
(Jackson) antibodies at 37uC for 1 h. DNA was stained with
Hoechst 33258 at room temperature (5 min for 293 T-REx
inducible cells or 90 sec for HeLa and NPC-TW01 cells). Slides
were mounted with mounting medium (H1000, Vector) and
observed by fluorescence microscopy (Axioskop 49 FL, Ziess).
Time-lapse Microscopy
To capture fluorescence images of living cells, GFP-H2B-HeLa
cells were seeded into 6-well plates and transfected with DsRed-
BGLF4, DsRed-K102I or DsRed expressing plasmids. At 6 h post
transfection, fields of view were selected and cells were subjected to
monitoring every 10 min over a 18 h duration under an
automated inverted fluorescence microscope (Axiovert 200M,
Zeiss). Images were captured by Metamorph software (Universal
Imaging). During imaging, cells were supplemented with 5% CO2
and a heat stage was used to maintain them at 37uC.
MTT Assay
To measure cell proliferation, 1610
3 293 T-REx inducible cells
or 2610
3 NPC-TW01 T-REx inducible cells in 200 ml medium
were seeded into 96-well plates in triplicate with or without Dox
(100 ng/ml for 293 T-REx or 50 ng/ml for NPC-TW01 T-REx).
An MTT assay was performed every 24 h after cell seeding. In
brief, the medium was aspirated and replenished with fresh
medium containing MTT (1 mg/ml, Sigma). After incubation at
37uC with 5% CO2 for 4 h, the medium with MTT was removed
and 100 ml DMSO was added to dissolve formazan crystals. The
96-well plates were shaken for 10 min at room temperature to
make sure all the crystals were completely dissolved. Then
absorbance was detected at 550 nm using an ELISA reader.
The percentage of cell proliferation against the control was
calculated by dividing the absorbance of cells treated with Dox by
the absorbance of cells without Dox treatment.
Analysis of Micronucleus Formation
To analyze the formation of micronuclei (MN), slide-cultured
293 T-REx V4, B22 and K9 cells or NPC-TW01 T-REx VIT7
and KIT2 cells were incubated with Dox for 72 h. Cells were fixed
with 4% paraformaldehyde at room temperature for 20 min and
stained with Hoechst33258 for 5 min. Micronuclei were examined
using fluorescence microscopy (Axioskop 49 FL, Ziess). At least
1000 cells were counted for each experiment.
Reporter Assay
To investigate whether BGLF4 regulates cyclin D1and ZBRK1
promoter activity, 5610
5 Saos-2 cells were seeded into 6-well
plates and transfected with reporter gene plasmid CCND1-P or
ZBRK1-B along with expression plasmids as indicated. The
amount of total DNA was kept constant by supplementing vector
pEGFP-C1. pWP1 (pCMV-Renilla reniformis) was co-transfected in
each reaction for normalizing transfection efficiencies. Luciferase
activity was determined with the dual-luciferase assay system
(Promega) at 48 h post transfection.
Supporting Information
Figure S1 Comparison of BGLF4 expression levels in
various cell lines. NA cell line is a recombinant Akata EBV-
converted NPC-TW01 line. EREV8 and Maxi EBV cell line are
derived from 293TREx_Flag_ERTA cell line. EREV8 cells were
generated by infecting 293TREx_Flag_ERTA with Akata EBV by
cocultivation with EBV-producing B cells. 293-Maxi EBV harbors
the EBV bacmid Maxi. NA cells were reactivated with 40 ng 12-
O-tetradecanoylphorbol-13-acetate-3 mM sodium butyrate
(TPA/SB) for 24 h. EREV8 and Maxi EBV was induced with
100 ng/ml Dox for 24 h for the expression of Rta to induce lytic
cycle progression. B22 is a 293 T-REx BGLF4 inducible cell line,
which was induced with100 ng/ml Dox for 24 h for BGLF4
expression. HeLa cells were seeded at a concentration of
2610
6 cells per 10-cm dish and transfected with 5 mg GFP-
BGLF4 and harvested at 24 h post transfection. The protein
expression levels of BGLF4 were resolved by 10% SDS-PAGE and
immunoblotted with specific antibodies. GAPDH served as a
loading control.
(TIF)
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PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e39217Figure S2 The kinase activity of viral protein kinase in
S.cerevisiae cdc28-13. (A) S.cerevisiae cdc28-13 with protein
expression as indicated was cultured in 10 ml Ura-SC broth to an
OD at 600 nm of 1.0. The yeast extracts were collected for IP-
kinase assay. EBV BGLF4, HCMV UL97 and human Cdc2 were
immunoprecipitated with HA antibody (HA.11, Covance). The
precipitated proteins were detected using HA antibody. (B) For in
vitro kinase assay, the immunoprecipitates were incubated with
kinase buffer (20 mM Tris-HCl, 1 mM EDTA, 1 mM DTT,
10 mM MgCl2, 0.2 mM Na3VO4, 100 mM ATP) containing[/
2
32P]ATP with 1 mg histone H1 (Calbiochem) at 30uC for
30 min. After kinase reaction, proteins were resolved by 12%
SDS-PAGE. Gels were dried and subjected to autoradiography for
12 h.
(TIF)
Figure S3 Expression kinetics of BGLF4 in 293 T-REx
BGLF4 inducible cells. (A) Various 293 T-REx BGLF4
inducible clones, B9, B10, B17, B19, B20 and B22, were treated
with 100 ng/ml doxycycline (Dox) for 24 h. The BGLF4 and
GAPDH proteins were resolved by 10% SDS-PAGE and
immunoblotted with specific antibodies. GAPDH served as a
loading control. (B) B22 cells were induced with 100 ng/ml Dox
for the times indicated. The proteins were displayed by SDS-
PAGE and detected with specific antibodies. (C) Slide cultured B9,
B20 and B22 cells were incubated with 100 ng/ml Dox. At 24 h
post induction (hpi), cells were fixed with 4% paraformaldehyde
and stained for BGLF4 with monoclonal antibody 2224 and DNA
with Hoechst 33258. (D) Slide cultured B22 cells were incubated
with 100 ng/ml Dox, harvested at the time points indicated and
stained for BGLF4 and DNA. Chromosome condensation was
observed at 6 hpi in B22 cells. (E) B9, B20 and B22 cells were
seeded in 96-well plate in a triplicate manner and induced with
100 ng/ml Dox for the expression of BGLF4. At 24, 48, 72, 96
and 120 hpi, an MTT assay was performed and the optical
densities (OD) were determined by spectrophotometry at 550 nm.
(TIF)
Figure S4 Expression kinetics of BGLF4 in NPC-TW01
T-REx BGLF4 inducible cells. (A) The NPC-TW01 T-REx
BGLF4 inducible clones KIT1, KIT2, KIT3, KIT20, KIT21 and
KIT22 were treated with 50 ng/ml doxycycline (Dox) for 24 h.
The BGLF4 protein was resolved by 10% SDS-PAGE and
immunoblotted with specific antibodies. GAPDH served as a
loading control. (B) KIT2 cells were induced with 50 ng/ml Dox
and cell extracts were collected at the time points indicated. The
protein expression was displayed by SDS-PAGE and detected with
specific antibodies. (C) Slide cultured KIT2 and KIT21 cells were
incubated with 50 ng/ml Dox. At 60 h post induction (hpi), cells
were fixed with 4% paraformaldehyde and stained for BGLF4
with monoclonal antibody 2224 and DNA with Hoechst 33258.
More than 95% of the cells expressed BGLF4.
(TIF)
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